This Article Full Text Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cherr, G. S. Articles by Geary, R. L. Search for Related Content PubMed PubMed Citation Articles by Cherr, G. S. Articles by Geary, R. L. Related Collections Restenosis Animal models of human disease Other Vascular biology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:161.)
© 2002 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Metalloproteinase Inhibition and the Response to Angioplasty and Stenting in Atherosclerotic Primates

Gregory S. Cherr; Stephen J. Motew; Jeffrey A. Travis; Juergen Fingerle; Larry Fisher; Mike Brandl; J. Koudy Williams; Randolph L. Geary

From the Departments of Surgery (G.S.C., S.J.M., J.A.T., R.L.G.) and Pathology (J.K.W.) of the Wake Forest University School of Medicine, Winston-Salem, NC, in collaboration with F. Hoffmann-La Roche (J.F., L.F., M.B.), Basel, Switzerland.

Correspondence to Randolph L. Geary, MD, FACS, Division of Surgical Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157. E-mail rgeary{at}wfubmc.edu

Determinants of restenosis after angioplasty include constrictive remodeling and intimal hyperplasia. Both processes require extensive matrix turnover, so matrix metalloproteinases (MMPs) have become potential targets of antirestenosis therapies. We studied the effects of RO113-2908, a broad-spectrum MMP inhibitor (MMPI), on the response to iliac artery angioplasty and stenting in atherosclerotic cynomolgus monkeys. Lumen diameter (LD) was measured angiographically, and artery wall geometry was assessed after perfusion-fixation at 4 weeks. Angiogenesis was measured in subcutaneous polyvinyl alcohol disks. Treatment provided significant, systemic MMP inhibitory activity (97±2.2% inhibition of 25 nmol/L MMP-12 by serum) and inhibited angiogenesis (P=0.007). In contrast, loss of gain in LD (P=0.73) and constrictive remodeling (external elastic lamina area ratio [injured/uninjuredx100]: MMPI, 106.3±9.6% vs control, 119.9±7.2%; P=0.27) were not substantially improved 4 weeks after angioplasty. Treatment also failed to reduce intimal hyperplasia after angioplasty (intimal area [mm²]: 1.4±0.3 vs 1.6±0.2, P=0.65) or stenting (2.4±0.2 vs 2.8±0.2, P=0.12). In summary, inhibition of MMP activity reduced angiogenesis but failed to prevent constrictive remodeling or intimal hyperplasia after angioplasty and stenting in atherosclerotic primates. Additional research is needed to define the spectrum of matrix-degrading proteases critical in healing atherosclerotic arteries after angioplasty.

Key Words: restenosis • constrictive remodeling • metalloproteinases • angioplasty • stents

This article has been cited by other articles:

				A. Dwivedi, S. C. Slater, and S. J. George MMP-9 and -12 cause N-cadherin shedding and thereby {beta}-catenin signalling and vascular smooth muscle cell proliferation Cardiovasc Res, January 1, 2009; 81(1): 178 - 186. [Abstract] [Full Text] [PDF]

				S. Janssens and H. R. Lijnen What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res, February 15, 2006; 69(3): 585 - 594. [Abstract] [Full Text] [PDF]

				J. P.G. Sluijter, D. P.V. de Kleijn, and G. Pasterkamp Vascular remodeling and protease inhibition-bench to bedside Cardiovasc Res, February 15, 2006; 69(3): 595 - 603. [Abstract] [Full Text] [PDF]

				A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF]

				M. M. Islam, C. D. Franco, D. W. Courtman, and M. P. Bendeck A Nonantibiotic Chemically Modified Tetracycline (CMT-3) Inhibits Intimal Thickening Am. J. Pathol., October 1, 2003; 163(4): 1557 - 1566. [Abstract] [Full Text] [PDF]

				C. B Jones, D. C Sane, and D. M Herrington Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome Cardiovasc Res, October 1, 2003; 59(4): 812 - 823. [Abstract] [Full Text] [PDF]

				G. Pasterkamp, M. J. Sierevogel, D. P.V. de Kleijn, B. H. Strauss, R. L. Geary, and G. S. Cherr MMP Inhibition and Lumen Loss After Balloon Angioplasty or Stenting * In Response Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1241 - 1241. [Full Text] [PDF]

				C. Li, W. J. Cantor, N. Nili, R. Robinson, L. Fenkell, Y. L. e Tran, H. A. Whittingham, W. Tsui, A. N. Cheema, J. D. Sparkes, et al. Arterial repair after stenting and the effects of gm6001, a matrix metalloproteinase inhibitor J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1852 - 1858. [Abstract] [Full Text] [PDF]

				A. H. Baker, D. R. Edwards, and G. Murphy Metalloproteinase inhibitors: biological actions and therapeutic opportunities J. Cell Sci., January 10, 2002; 115(19): 3719 - 3727. [Abstract] [Full Text] [PDF]